Bud Genius Provides Solution to Major Flaw in Medical Marijuana Industry

Company developed system to help assure that patients receive the right strain for their specific condition

Bud Genius, Inc. (www.BGMedtech.com) (OTC: RIGH), a leading laboratory for cannabis testing and profiling, developer of data-driven rating systems for marijuana strains, brand and retail development specialist, and licensee of celebrity-endorsed marijuana and hemp related merchandise, commented today on a recent article in Mother Nature Network, listing over a dozen ailments that cannabis has been shown to help.

Studies have shown that cannabis can be effective in helping patients suffering from a variety of conditions, including: cancer, diabetes, epilepsy, autism, Alzheimer’s disease, arthritis, and glaucoma, to name a few.

However, the article fails to mention that there is an enormous problem with the current medical cannabis system in the United States. Patients often do not know if the strain they are purchasing will have the desired effect or will help their specific condition, even if the cannabis has the same name as one they have previously purchased.

Marijuana growing techniques differ from farmer to farmer, and often produce results that vary widely in potency and chemical composition for strains labeled with the same name. Moreover, the name a strain is given is often arbitrary. What one dispensary calls, “Kush Green” for example, may be an entirely different strain than what is sold in another dispensary with the same name, or even within the same dispensary two weeks later.

“Clearly, this would not occur in the medical or pharmaceutical industry,” said Angel Stanz, CEO of Bud Genius. “When you buy Tylenol, you know it is the same, whether you purchase it in Walgreens or CVS, in any city in America,” he stated. “Patients should demand the same assurances from the medical marijuana industry.”

Bud Genius has built the industry’s leading data collection platform, which analyzes each cannabis strain’s potency and ratio of compounds, and also uses patient feedback to create a “Model of Appropriate Use and Predicted Outcomes.”

For instance, a patient may be looking for a strain that reduces their back pain, but does not cause sleepiness. Another patient may want a strain that helps her sleep at night, but will not cause hunger. Bud Genius is able to provide detailed information to collectives, caregivers and patients, so that they can make informed decisions and select the best possible strain for their specific condition.

“We have put countless hours into developing and refining this system so that medical collectives, caregivers and patients can now have an open, intelligent discussion about the health benefits of cannabis, based on real data,” Stanz commented. “Knowing how each strain can produce various healing affects is good for the patient, good for the collective, and good for the industry. We are proud to be leading this effort.”

For more information on Bud Genius, call (855) 723-3283, or visit www.BGMedtech.com.

About Bud Genius:

An early leader in the cannabis industry, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius’ mission is to expand across the US and abroad, serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories, strain certification, data collection, online reporting, and product development.

For more information please visit: www.BudGenius.com

Connect:

Website: www.BudGenius.com

Twitter: Twitter.com/BudGenius

Forward Looking Statements:

This press announcement includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of company’s management and are subject to significant risks and uncertainties. Forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, competitive factors, and other matters. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Bud Genius, Inc.Randall Huft, 855-723-3283PR@BudGenius.com

RightSmile (CE) (USOTC:RIGH)
Historical Stock Chart
From Mar 2024 to Apr 2024